Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Apr;57(4):229-230.
doi: 10.1016/j.jaac.2018.01.019.

Meta-Analyses in Child and Adolescent Psychiatry: Getting Closer to Clinical Practice

Affiliations
Editorial

Meta-Analyses in Child and Adolescent Psychiatry: Getting Closer to Clinical Practice

Samuele Cortese. J Am Acad Child Adolesc Psychiatry. 2018 Apr.

Abstract

Rigorously conducted meta-analyses provide evidence synthesis that has the potential to inform daily clinical decision making and development of clinical guidelines. In the past decade, there has been an increasing number of studies on pharmacologic and non-pharmacologic treatments for childhood and adolescent psychiatric disorders. Given this large body of research, busy clinicians might tend to rely on meta-analyses, rather than individual trials, to keep abreast of the evidence base supporting intervention strategies in child and adolescent psychiatry. Many meta-analyses focused on treatments for child and adolescent mental health problems have primarily addressed the question: Is treatment X more efficacious/effective (or safer) than the control condition? This is clearly an important starting point for clinicians when discussing with their patients and families the benefits and risks of treatment X, but clinicians need to know more. For instance, they might look for the evidence base to answer the following questions: Is treatment X the most efficacious and effective (or safest) option for my patient? When will treatment X likely start working? If the dose or intensity of the treatment does not seem to be effective, is it worthwhile to increase it? And if so, how?

PubMed Disclaimer

Comment in

  • Unbalanced risk-benefit analysis of ADHD drugs.
    Faltinsen EG, Gluud C, Simonsen E, Zwi M, Storebø OJ. Faltinsen EG, et al. Lancet Psychiatry. 2018 Nov;5(11):870. doi: 10.1016/S2215-0366(18)30334-1. Epub 2018 Oct 26. Lancet Psychiatry. 2018. PMID: 30401440 No abstract available.

Comment on

Substances